Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
15/05/2024 | 22:30 | GlobeNewswire Inc. | Elevai Labs Inc. Reports First Quarter 2024 Financial Results | NASDAQ:ELAB | Elevai Labs Inc |
15/05/2024 | 22:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ELAB | Elevai Labs Inc |
09/05/2024 | 22:01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ELAB | Elevai Labs Inc |
02/05/2024 | 14:30 | GlobeNewswire Inc. | Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity | NASDAQ:ELAB | Elevai Labs Inc |
01/05/2024 | 22:00 | GlobeNewswire Inc. | Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare | NASDAQ:ELAB | Elevai Labs Inc |
01/05/2024 | 15:00 | GlobeNewswire Inc. | Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments | NASDAQ:ELAB | Elevai Labs Inc |
29/04/2024 | 15:45 | GlobeNewswire Inc. | Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments | NASDAQ:ELAB | Elevai Labs Inc |
22/04/2024 | 14:00 | GlobeNewswire Inc. | ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months | NASDAQ:ELAB | Elevai Labs Inc |
29/03/2024 | 17:00 | GlobeNewswire Inc. | Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results | NASDAQ:ELAB | Elevai Labs Inc |
18/03/2024 | 13:51 | InvestorsHub NewsWire | Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market | NASDAQ:ELAB | Elevai Labs Inc |
24/01/2024 | 14:30 | GlobeNewswire Inc. | ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office | NASDAQ:ELAB | Elevai Labs Inc |
17/01/2024 | 15:07 | InvestorsHub NewsWire | ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach | NASDAQ:ELAB | Elevai Labs Inc |
16/01/2024 | 16:05 | InvestorsHub NewsWire | ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology | NASDAQ:ELAB | Elevai Labs Inc |
02/01/2024 | 15:15 | GlobeNewswire Inc. | ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences | NASDAQ:ELAB | Elevai Labs Inc |
11/12/2023 | 15:15 | GlobeNewswire Inc. | Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023 | NASDAQ:ELAB | Elevai Labs Inc |
07/12/2023 | 15:41 | GlobeNewswire Inc. | ELEVAI Labs, Inc. Expands International Distribution into Europe | NASDAQ:ELAB | Elevai Labs Inc |
29/11/2023 | 15:00 | GlobeNewswire Inc. | Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products | NASDAQ:ELAB | Elevai Labs Inc |
24/11/2023 | 19:38 | PR Newswire (US) | ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering | NASDAQ:ELAB | Elevai Labs Inc |
24/11/2023 | 18:00 | GlobeNewswire Inc. | Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB) | NASDAQ:ELAB | Elevai Labs Inc |
23/06/2005 | 23:13 | Business Wire | Eon Labs Receives Final Approval for Bupropion HCl, ER 200mg Tablets and Will Begin Shipping Immediately | NASDAQ:ELAB | Elevai Labs Inc |
13/06/2005 | 23:41 | Business Wire | Appeals Court Affirms that Eon Labs' Itraconazole Does Not Infringe Janssen's Patent | NASDAQ:ELAB | Elevai Labs Inc |
24/02/2004 | 20:34 | PR Newswire (US) | Pacific Exchange to Trade Six New Options | NASDAQ:ELAB | Elevai Labs Inc |